

BLA 103353/S-5196

SUPPLEMENT APPROVAL

AMGEN, INC.
Attention: Jose Alberto Huerta Salazar
Senior Manager, Regulatory Affairs
One Amgen Center Drive
Mail Stop: 27-2-D
Thousand Oaks, CA 91320-1799

Dear Mr. Salazar:

Please refer to your supplemental biologics license application (sBLA), dated and received July 31, 2020 and your amendments, submitted under section 351(a) of the Public Health Service Act for Neupogen (filgrastim) for Injection.

This Prior Approval supplemental biologics application provides for revisions to the approved Package Insert (PI) and Medication Guide (MG) for Neupogen (filgrastim) to add information regarding an increased risk of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) associated with the use of filgrastim in conjunction with chemotherapy/radiation therapy in patients with breast and lung cancer. The sections of labeling affected are:

In the PI:

- Highlights
- Warnings and Precautions
- Adverse Reactions
- Patient Counseling Information

In the MG:

- What are the possible side effects of Neupogen?

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at

FDA.gov,¹ that is identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert, and Medication Guide) and include the labeling changes proposed in any pending “Changes Being Effectuated” (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effectuated” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

As required under 21 CFR 601.12(f)(4), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

All promotional materials for your drug product that include representations about your drug product must be promptly revised to make it consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 601.12(a)(4)]. The revisions to your promotional materials should include prominent disclosure of the important new safety information that appears in the revised labeling.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 601.12(a)(4).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Lori Anne Wachter, RN, BSN, RAC (US), Acting Regulatory Project Manager for Safety, at 301 796-3975.

Sincerely,

{See appended electronic signature page}

Rosanna Setse, MD, PhD
Acting Deputy Director for Safety
Division of Non-malignant Hematology
Office of Cardiology, Hematology, Endocrinology
and Nephrology
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ROSANNA W SETSE
01/05/2021 04:19:39 PM